Products for Research Use Only
RegisterLogin

Fenlean

CAT: 0804-HY-123506-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-123506-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Fenlean, a natural squamosamide derivative, is a Src tyrosine kinase inhibitor. Fenlean can inhibit over-activated microglia and protect dopaminergic neurons. Fenlean can attenuate neuroinflammation in Parkinson's disease models[1][2][3].
CAS Number
863193-70-8
UNSPSC
12352005
Target
Src
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/fenlean.html
Purity
99.56
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(/C(C1=CC(OC)=CC=C1OC)=C/C2=CC=C(C(OC)=C2)O)NCCC3=CC=C(C=C3)O
Molecular Formula
C26H27NO6
Molecular Weight
449.50
References & Citations
[1]Tai W, et, al. Inhibition of Src tyrosine kinase activity by squamosamide derivative FLZ attenuates neuroinflammation in both in vivo and in vitro Parkinson's disease models. Neuropharmacology. 2013 Dec;75:201-12. |[2]Cheng LB, et, al. Squamosamide derivative FLZ protects retinal pigment epithelium cells from oxidative stress through activation of epidermal growth factor receptor (EGFR) -AKT signaling. Int J Mol Sci. 2014 Oct 17;15 (10) :18762-75. |[3]Ye X, et, al. FLZ inhibited γ-secretase selectively and decreased Aβ mitochondrial production in APP-SH-SY5Y cells. Naunyn Schmiedebergs Arch Pharmacol. 2014 Jan;387 (1) :75-85.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Alternative Products

CatalogName
BA9021-1Fenlean

Popular Products